keyword
MENU ▼
Read by QxMD icon Read
search

prostate cancer clinical trials

keyword
https://www.readbyqxmd.com/read/28213657/the-roles-of-uvb-and-vitamin-d-in-reducing-risk-of-cancer-incidence-and-mortality-a-review-of-the-epidemiology-clinical-trials-and-mechanisms
#1
REVIEW
Meis Moukayed, William B Grant
Global cancer incidence and mortality rates are high and increasing. Thus, it is imperative to find novel solutions to preventing cancer incidence and treating it at an affordable yet efficacious manner. The solar UVB-vitamin D-cancer hypothesis was first proposed in 1980 based on a geographical ecological study. Since then, numerous ecological and observational studies as well as studies of mechanisms have provided support for the hypothesis. However, observational studies have not provided consistent support, in part due to using a single blood draw from any season to use for serum 25-hydroxyvitamin D [25(OH)D] concentration in prospective studies with long follow-up times...
February 17, 2017: Reviews in Endocrine & Metabolic Disorders
https://www.readbyqxmd.com/read/28196065/revisiting-a-longstanding-clinical-trial-exclusion-criterion-impact-of-prior-cancer-in-early-stage-lung-cancer
#2
Sandi L Pruitt, Andrew L Laccetti, Lei Xuan, Ethan A Halm, David E Gerber
BACKGROUND: Early-stage lung cancer represents a key focus of numerous multicenter clinical trials, but common exclusion criteria such as a prior cancer diagnosis may limit enrollment. We examined the prevalence and prognostic impact of a prior cancer diagnosis among patients with early-stage lung cancer. METHODS: We identified patients>65 years of age with early-stage lung cancer diagnosed 1996-2009 in the Surveillance, Epidemiology, and End Results-Medicare linked database...
February 14, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28190749/role-of-radical-prostatectomy-in-metastatic-prostate-cancer-a-review
#3
REVIEW
Michael J Metcalfe, Marc C Smaldone, Daniel W Lin, Ana M Aparicio, Brian F Chapin
CONTEXT: Recent demonstration of efficacy with the use of chemohormonal therapy for men with metastatic prostate cancer (mPCa) has expanded the therapeutic options for these patients. Furthermore, multimodal therapy to treat systemic disease in the context of locoregional control has gained increasing interest. Concomitantly, the role of radical prostatectomy (RP) in multimodal treatment for locally advanced prostate cancer is expanding. As a result, there is interest in investigating the potential benefit of cytoreductive RP in mPCa...
February 9, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28190704/high-risk-prostate-cancer-and-radiotherapy-the-past-and-the-future-a-benchmark-for-a-new-mixed-beam-radiotherapy-approach
#4
Giulia Marvaso, Barbara A Jereczek-Fossa, Giulia Riva, Camilla Bassi, Cristiana Fodor, Delia Ciardo, Raffaella Cambria, Floriana Pansini, Dario Zerini, Paolo De Marco, Federica Cattani, Ottavio De Cobelli, Roberto Orecchia
BACKGROUND: The prognosis for patients with high-risk prostate cancer is poor. No consensus exists on the most effective treatment. The aim of this retrospective study was to identify the biochemical progression-free survival and the toxicity profile of patients with localized high-risk prostate cancer treated with external beam radiation therapy. These results will constitute a benchmark for a prospective "mixed beam" trial: a boost with carbon ions followed by a pelvic photon intensity-modulated radiotherapy (NCT02672449 [clinicaltrials...
January 18, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28190638/long-term-toxicity-and-health-related-quality-of-life-after-single-fraction-high-dose-rate-brachytherapy-boost-and-hypofractionated-external-beam-radiotherapy-for-intermediate-risk-prostate-cancer
#5
N Shahid, A Loblaw, H T Chung, P Cheung, E Szumacher, C Danjoux, R Sankreacha, L Zhang, A Deabreu, A Mamedov, G Morton
AIMS: To report health-related quality of life (HRQOL) and toxicity in prostate cancer patients treated with single-fraction high dose rate (HDR) brachytherapy boost and external beam radiotherapy (EBRT). MATERIALS AND METHODS: Patients with intermediate-risk prostate cancer were accrued to a phase II clinical trial of 15 Gy HDR boost and EBRT to a dose of 37.5 Gy in 15 fractions. HRQOL (Expanded Prostate Cancer Index Composite [EPIC]), urinary symptoms (International Prostate Symptom Score [IPSS]), erectile function (International Index of Erectile Function [IIEF]) and toxicity (Common Terminology Criteria for Adverse Events [CTCAE], version 3...
February 9, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/28188689/sentinel-node-biopsy-for-prostate-cancer-report-from-a-consensus-panel-meeting
#6
Henk G van der Poel, Esther M Wit, Cenk Acar, Nynke S van den Berg, Fijs W B van Leeuwen, Renato A Valdes Olmos, Alexander Winter, Friedhelm Wawroschek, Fredrik Liedberg, Steven Maclennan, Thomas Lam
OBJECTIVE: To explore the evidence and knowledge gaps in sentinel node biopsy (SNB) in prostate cancer by a consensus panel of experts. METHODS: A two-round Delphi survey among experts was followed by a consensus panel meeting of 16 experts in February 2016. Agreement voting was performed using the RAND/University of California, Los Angeles Appropriateness Methodology on 150 statements in 9 domains. The disagreement index based on the interpercentile range-adjusted for symmetry score was used to assess consensus and non-consensus among panel members RESULTS: Consensus was obtained on 91 of 150 (61%) statements...
February 10, 2017: BJU International
https://www.readbyqxmd.com/read/28185916/dna-vaccines-for-prostate-cancer
#7
REVIEW
Christopher D Zahm, Viswa Teja Colluru, Douglas G McNeel
DNA vaccines offer many advantages over other anti-tumor vaccine approaches due to their simplicity, ease of manufacturing, and safety. Results from several clinical trials in patients with cancer have demonstrated that DNA vaccines are safe and can elicit immune responses. However, to date few DNA vaccines have progressed beyond phase I clinical trial evaluation. Studies into the mechanism of action of DNA vaccines in terms of antigen-presenting cell types able to directly present or cross-present DNA-encoded antigens, and the activation of innate immune responses due to DNA itself, have suggested opportunities to increase the immunogenicity of these vaccines...
February 6, 2017: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28181675/a-placebo-controlled-double-blinded-randomized-pilot-study-of-combination-phytotherapy-in-biochemically-recurrent-prostate-cancer
#8
M Diana van Die, Scott G Williams, Jon Emery, Kerry M Bone, Jeremy M G Taylor, Elizabeth Lusk, Marie V Pirotta
BACKGROUND: Men with biochemical recurrence of prostate cancer following local therapies often use natural supplements in an attempt to delay metastases and/or avoid the need for more aggressive treatments with undesirable side-effects. While there is a growing body of research into phytotherapeutic agents in this cohort, with some promising results, as yet no definitive recommendations can be made. This pilot study was undertaken to assess the feasibility of a fully-powered study to examine the effects of this phytotherapeutic intervention (containing turmeric, resveratrol, green tea and broccoli sprouts) on PSA doubling time in men with biochemical recurrence with a moderate PSA rise rate...
February 9, 2017: Prostate
https://www.readbyqxmd.com/read/28171710/clinical-outcomes-and-survival-surrogacy-studies-of-prostate-specific-antigen-declines-following-enzalutamide-in-men-with-metastatic-castration-resistant-prostate-cancer-previously-treated-with-docetaxel
#9
Andrew J Armstrong, Fred Saad, De Phung, Carl Dmuchowski, Neal D Shore, Karim Fizazi, Mohammad Hirmand, David Forer, Howard I Scher, Johann De Bono
BACKGROUND: In the AFFIRM trial, enzalutamide significantly increased overall survival (OS) for men with metastatic castration-resistant prostate cancer (mCRPC) after chemotherapy versus placebo and significantly decreased prostate-specific antigen (PSA) levels. The goal of this post hoc analysis was to associate levels of PSA decline from baseline after enzalutamide with clinical outcomes in the postchemotherapy mCRPC setting. METHODS: Men in the AFFIRM trial (n = 1199) were grouped by maximal PSA decline in the first 90 days of treatment...
February 7, 2017: Cancer
https://www.readbyqxmd.com/read/28169118/bone-health-and-bone-targeted-therapies-for-prostate-cancer-a-programme-in-evidence-based-care-cancer-care-ontario-clinical-practice-guideline
#10
S M H Alibhai, K Zukotynski, C Walker-Dilks, U Emmenegger, A Finelli, S C Morgan, S J Hotte, E Winquist
AIMS: To make recommendations with respect to bone health and bone-targeted therapies in men with prostate cancer. MATERIALS AND METHODS: A systematic review was carried out by searching MEDLINE, EMBASE and the Cochrane Library from inception to January 2016. Systematic reviews and randomised-controlled trials were considered for inclusion if they involved therapies directed at improving bone health or outcomes such as skeletal-related events, pain and quality of life in patients with prostate cancer either with or without metastases to bone...
February 3, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/28165653/novel-biparametric-mri-and-targeted-biopsy-improves-risk-stratification-in-men-with-a-clinical-suspicion-of-prostate-cancer-improd-trial
#11
Ivan Jambor, Peter J Boström, Pekka Taimen, Kari Syvänen, Esa Kähkönen, Markku Kallajoki, Ileana Montoya Perez, Tommi Kauko, Jaakko Matomäki, Otto Ettala, Harri Merisaari, Aida Kiviniemi, Peter B Dean, Hannu J Aronen
PURPOSE: To evaluate the role of a 3T biparametric magnetic resonance imaging (bpMRI), T2 -weighted imaging, and three separate diffusion-weighted imaging acquisitions combined with targeted biopsy (TB) for improving risk stratification of men with elevated prostate-specific antigen (PSA). MATERIALS AND METHODS: Between March 2013 and February 2015, 175 men with a clinical suspicion of prostate cancer (PCa) were offered bpMRI (NCT01864135) based on a suspicion of PCa (two repeated PSA measurements in the range 2...
February 6, 2017: Journal of Magnetic Resonance Imaging: JMRI
https://www.readbyqxmd.com/read/28163805/evidence-based-guideline-recommendations-on-multiparametric-magnetic-resonance-imaging-in-the-diagnosis-of-prostate-cancer-a-cancer-care-ontario-clinical-practice-guideline
#12
Masoom A Haider, Xiaomei Yao, Andrew Loblaw, Antonio Finelli
This clinical guideline focuses on: 1) the use of multiparametric magnetic resonance imaging (mpMRI) in diagnosing clinically significant prostate cancer (CSPC) in patients with an elevated risk of CSPC and who are biopsy-naïve; and 2) the use of mpMRI in diagnosing CSPC in patients with a persistently elevated risk of having CSPC and who have a negative transrectal ultrasound (TRUS)-guided systematic biopsy. The methods of the Practice Guideline Development Cycle were used. MEDLINE, EMBASE, the Cochrane Library (1997‒April 2014), main guideline websites, and relevant annual meeting abstracts (2011‒2014) were searched...
January 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28161323/a-multicenter-phase-i-study-of-cabazitaxel-mitoxantrone-and-prednisone-for-chemotherapy-na%C3%A3-ve-patients-with-metastatic-castration-resistant-prostate-cancer-a-department-of-defense-prostate-cancer-clinical-trials-consortium-study
#13
Rahul Aggarwal, Alan Bryce, Charles J Ryan, Andrea Harzstark, Christina Derleth, Won Kim, Terence Friedlander, Amy M Lin, Tammy Rodvelt-Bagchi, Mallika Dhawan, Li Zhang, Mina Lee, Eric Siebeneck, Jeffrey Hough, Eric J Small
BACKGROUND: Cabazitaxel plus prednisone has significant activity in patients with chemotherapy-naïve and pretreated metastatic castration-resistant prostate cancer (mCRPC). Mitoxantrone has antitumor activity in mCRPC and nonoverlapping mechanism of action and toxicity profile. OBJECTIVE: To establish the maximally tolerated dose of the combination of cabazitaxel, mitoxantrone, and prednisone. METHODS AND MATERIALS: Patients with chemotherapy-naïve mCRPC were prospectively enrolled in a multicenter phase 1 trial...
February 1, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28159496/androgen-deprivation-with-or-without-radiation-therapy-for-clinically-node-positive-prostate-cancer-lin-cc-gray-pj-jemal-a-efstathiou-ja-surveillance-and-health-services-research-program-intramural-research-american-cancer-society-atlanta-ga-ccl-aj-department
#14
Eggener Scott
BACKGROUND: Clinically lymph node-positive (cN+) prostate cancer (PCa) is an often-fatal disease. Its optimal management remains largely undefined given a lack of prospective, randomized data to inform practice. We sought to describe modern practice patterns in the management of cN+PCa and assess the effect of adding radiation therapy (RT) to androgen deprivation therapy (ADT) on survival using the National Cancer Data Base. METHODS: Patients with cN+PCa and without distant metastases diagnosed between 2004 and 2011 were included...
March 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28152894/engaging-managing-physicians-in-clinical-staging-prior-to-the-initiation-of-cancer-treatment
#15
Carol Huibregtse, Marija Bjegovich-Weidman, James L Weese
: 143 Background: Managing physicians (medical oncologist, radiation oncologist, surgeons) have a responsibility to clinically stage patients prior to the initiation of cancer treatment. Clinical staging not only directs the treatment plan, but identifies appropriate clinical trials and estimates prognosis. We sought to determine whether engagement of managing physicians would result in increased clinical staging for various types of cancer. METHODS: Baseline data on clinical staging for breast, colorectal (colon, rectal, anal, rectosigmoid junction)*, thoracic (lung esophageal)†, genitourinary (prostate, penis, testes)‡, and pancreatic primary cancers were obtained...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28152874/assessing-the-impact-of-restricted-follow-up-and-small-sample-sizes-on-survival-estimations-in-prostate-cancer-using-registry-data
#16
Victoria Paly, Andrew Briggs, Manpreet Sidhu, Esprit Ma, Vijayveer Bonthapally
: 294 Background: Economic evaluations in oncology aim to assess the value of new therapies in the long term based on clinical trial data that often have restricted follow-up times (< 5 years) and small sample sizes (< 500 patients). This requires the use of extrapolation assumptions on long-term survival that go beyond the observed data. In this analysis, differences in survival extrapolation methods are tested in samples of sizes and follow-up reflecting typical clinical trials against a background of known survival in prostate cancer from a US based cancer registry...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28152852/quality-of-radiation-therapy-referral-and-utilization-post-prostatectomy-a-population-based-study-of-time-trends
#17
Michael Donald Brundage, Earl Francis Cook, Qun Miao, Timothy P Hanna
: 286 Background: Adjuvant radiotherapy (ART) post-radical prostatectomy (RP) has been shown to benefit patients with pathologic T3 or margin-positive prostate cancer. It remains unclear whether early salvage radiotherapy (SRT) confers equivalent outcomes to ART. Practice Guidelines recommend referral to radiation oncology (RO) within 6 months of RP to discuss ART and SRT. The study objectives were to (1) assess post-RP referral patterns to RO; (2) describe ART and SRT utilization; and (3) compare time trends before and after seminal trials and guidelines were published...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28150523/flexible-modeling-of-the-hazard-rate-and-treatment-effects-in-long-term-survival-studies
#18
Yolanda Hagar, James J Dignam, Vanja Dukic
The effects of predictors on time to failure may be difficult to assess in cancer studies with longer follow-up, as the commonly used assumption of proportionality of hazards holding over an extended period is often questionable. Motivated by a long-term prostate cancer clinical trial, we contrast and compare four powerful methods for estimation of the hazard rate. These four methods allow for varying degrees of smoothness as well as covariates with effects that vary over time. We pay particular attention to an extended multiresolution hazard estimator, which is a flexible, semi-parametric, Bayesian method for joint estimation of predictor effects and the hazard rate...
January 1, 2017: Statistical Methods in Medical Research
https://www.readbyqxmd.com/read/28147927/a-case-report-of-enzalutamide-administration-in-a-dialysis-dependent-patient-with-castration-resistant-prostate-cancer
#19
Erica S Tsang, Marie de Haan, Bernhard J Eigl
Enzalutamide, an androgen receptor signaling inhibitor, is a standard of care treatment for metastatic castration-resistant prostate cancer. We present the first reported case of enzalutamide in a patient with end-stage renal disease, on dialysis. While there were no significant toxicities, a sustained increase in systolic blood pressure was maintained after starting enzalutamide, suggestive of a degree of drug accumulation. Further evaluation of novel hormonal agents in end-stage renal disease patients should be encouraged as this population is typically excluded from clinical trials...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28144973/minnelide-inhibits-androgen-dependent-castration-resistant-prostate-cancer-growth-by-decreasing-expression-of-androgen-receptor-full-length-and-splice-variants
#20
Sumit Isharwal, Shrey Modi, Nivedita Arora, Charles Uhlrich, Bhuwan Giri, Usman Barlass, Ayman Soubra, Rohit Chugh, Scott M Dehm, Vikas Dudeja, Ashok Saluja, Sulagna Banerjee, Badrinath Konety
BACKGROUND: With almost 30,000 deaths per year, prostate cancer is the second-leading cause of cancer-related death in men. Androgen Deprivation Therapy (ADT) has been the corner stone of prostate cancer treatment for decades. However, despite an initial response of prostate cancer to ADT, this eventually fails and the tumors recur, resulting in Castration Resistant Prostate Cancer (CRPC). Triptolide, a diterpene triepoxide, has been tested for its anti-tumor properties in a number of cancers for over a decade...
February 1, 2017: Prostate
keyword
keyword
58398
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"